This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Michael Byrne, Ph.D.
Director of In vivo Biology and Ophthalmology at Wave Life Sciences


Dr. Byrne has been with Wave Life Sciences, Inc. for three years where he serves as director of in vivo biology and ophthalmology. In that time his focus has been on assessing the utility of stereopure oligonucleotides as potential therapeutics for rare inherited retinal diseases. Prior to joining Wave, Dr. Byrne spent 9 years at RXi Pharmaceuticals where he advanced RXi’s self-delivering siRNA oligonucleotides to the clinic for treatment of retinal scarring associated with late-stage AMD.  Dr. Byrne received his Ph.D. from Northeastern University in Boston, MA where he studied microRNA expression patterns and impact on embryo development.

Agenda Sessions

  • Stereopure Oligonucleotides Produce Potent and Durable Activity in the Eye Supporting Their Development for Inherited Retinal Diseases